Endogene

Market position

Presented as an early-stage, research-driven company addressing a data gap in uterine health; the EIT Health/Dealroom profile lists no known external funding and the Genopole listing describes a pre-seed investment with a seed campaign underway. Recognition includes selection as winner of the 2026 Hello Tomorrow Challenge from more than 4,800 applicants and 100 finalists, and selection for Eli Lilly's inaugural virtual Gateway Labs program.

The company claims the first scalable, non-invasive window into the uterus via menstrual blood, patented collection and processing, access to rare disease-driving cells, the ability to sample longitudinally, and the largest high-resolution atlas of disease-driving cell states — contrasted with surgical biopsy and animal models. Genopole cites an advisory board including a key opinion leader in endometriosis plus business development and women's health experts.

Technology

The technology combines patented menstrual blood collection and lab processing, wet-lab molecular profiling, and computational modeling. Disclosed methods include whole genome methylation profiling of menstrual stem cells for endometriosis biomarker discovery and single-cell transcriptomic signature analysis used to predict drug efficacy and identify responder subgroups. Website material references cell types profiled including stromal, epithelium, cervix, endothelial, macrophages, T cells and NK cells, and an atlas of disease-driving cell states. Genopole describes the diagnostic approach as based on epigenetic biomarkers in self-collected menstrual blood samples.

Go-to-market

Go-to-market is centered on strategic collaborations: biopharma partnerships around proprietary datasets and drug development, clinical-center collaborations for patient recruitment and molecular profiling, and academic research collaborations. The company also builds visibility through peer-reviewed publications, conference presentations (SEUD 2026), accelerator programs (Entrepreneur First; Eli Lilly Gateway Labs) and competitions (Hello Tomorrow Challenge). Genopole notes it seeks collaborations with research laboratories, hospitals, pharmaceutical companies and biotechs working on endometriosis treatments.

Pharmaceutical and biopharma companies, hospitals and clinics, and research institutions; ultimately patients with endometriosis and other uterine diseases, and the physicians managing them.

Geography

Headquartered in Paris, France (3 boulevard de Sébastopol, 75001 Paris), with an R&D laboratory at the Genopole biocluster in Evry-Courcouronnes. The Entrepreneurs First portfolio lists the company under Paris. The Eli Lilly Gateway Labs program it joined kicked off in London.

History

The company is listed in the Entrepreneurs First portfolio directory as EndoGene.Bio and, per Genopole, obtained pre-seed investment from the Entrepreneur First accelerator and partnered with two hospitals to validate its proof of concept, with a seed funding campaign underway at the time of that listing. Its scope as presented on its own website has broadened from an endometriosis diagnostic to a wider uterine-health data platform (Endoprofile). Company news items report peer-reviewed publications in December 2025 and May 2026, research presented at SEUD 2026 in April 2026, selection for the inaugural virtual Eli Lilly and Company Gateway Labs program in June 2026, and winning the 2026 Hello Tomorrow Challenge in June 2026.

Risks & controversies

No controversies are reported in the sources. Risk-relevant observations: funding data is thin — the EIT Health/Dealroom profile records no known external funding, and the Genopole listing describes only a pre-seed investment with a seed round in progress. The company is pre-commercial, with a diagnostic still in development and no disclosed regulatory approvals. Note also that a similarly named US medical device company, Endogenex (type 2 diabetes, Minnesota), is a distinct entity.